

AMENDMENTS TO THE CLAIMS

In the Claims:

1. (Currently amended) A chemically synthesized modified double-stranded short interfering ribonucleic nucleic acid (siRNA) molecule comprising a complementary sense strand and an antisense strand, wherein:
 - a. said sense strand and said antisense strand are each independently about 19 14 to 29 28 nucleotides in length; and
 - b. said antisense strand comprises about 14 to 28 nucleotides that are nucleotide sequence complementary to nucleic acid sequence encoding a vascular endothelial growth factor receptor 1 (VEGFr1) nucleotide sequence corresponding to SEQ ID NO:2752 or a portion thereof and vascular endothelial growth factor receptor 2 (VEGFr2) nucleotide sequence corresponding to SEQ ID NO:2752 or a portion thereof;
 - c. said sense strand of said siRNA molecule comprises a portion of said VEGFr1 and VEGFr2 nucleotide sequence of about 18 to about 27 nucleotides; and
 - d. said siRNA molecule comprises at least one 2'-O-methyl or 2'-deoxy-2'-fluoro nucleotide[.]
2. (Canceled)
3. (Currently amended) The double stranded nucleic acid siRNA molecule of claim 1, wherein said double stranded nucleic acid siRNA molecule comprises ribonucleotides.
4. (Canceled)
5. (Canceled)
6. (Canceled)

7. (Canceled)
8. (Canceled)
9. (Canceled)
10. (Canceled)
11. (Canceled)
12. (Canceled)
13. (Canceled)
14. (Currently amended) The ~~double stranded nucleic acid~~ siRNA molecule of claim 1, wherein purine nucleotides in the sense strand are 2'-deoxy purine nucleotides.
15. (Currently amended) The ~~double stranded nucleic acid~~ siRNA molecule of claim 1, wherein the one or more pyrimidine nucleotides present in the sense strand are 2'-deoxy-2'-fluoro pyrimidine nucleotides.
16. (Currently amended) The ~~double stranded nucleic acid~~ siRNA molecule of claim 1, wherein the sense strand includes a terminal cap moiety at the 5'-end, the 3'-end, or both of the 5' and 3' ends of the sense strand.
17. (Currently amended) The ~~double stranded nucleic acid~~ siRNA molecule of claim 16, wherein said terminal cap moiety is an inverted deoxy abasic moiety.
18. (Currently amended) The ~~double stranded nucleic acid~~ siRNA molecule of claim 1, wherein the one or more pyrimidine nucleotides present in said antisense strand are 2'-deoxy-2'-fluoro pyrimidine nucleotides.
19. (Currently amended) The ~~double stranded nucleic acid~~ siRNA molecule of claim 1, wherein the one or more purine nucleotides present in said antisense strand are 2'-O-methyl purine nucleotides.
20. (Currently amended) The ~~double stranded nucleic acid~~ siRNA molecule of claim 1, wherein the one or more purine nucleotides present in said antisense strand comprise 2'-deoxy- purine nucleotides.

21. (Currently amended) The ~~double stranded nucleic acid~~ siRNA molecule of claim 1, wherein said antisense strand comprises a phosphorothioate internucleotide linkage at the 3' end of said antisense strand.
22. (Currently amended) The ~~double stranded nucleic acid~~ siRNA molecule of claim 1, wherein said antisense strand comprises a terminal cap moiety at the 3' end of said antisense strand.
23. (Currently amended) The ~~double stranded nucleic acid~~ siRNA molecule of claim 22, wherein said terminal cap comprises an inverted deoxyabasic moiety.
24. (Canceled)
25. (Canceled)
24. (Canceled)
25. (Canceled)
26. (Canceled)
27. (Canceled)
28. (Canceled)
29. (Canceled)
30. (Canceled)
31. (Canceled)
32. (Currently amended) The ~~double stranded nucleic acid~~ siRNA molecule of claim 1, wherein the 5'-end of the antisense strand optionally includes a terminal phosphate group.
33. (Canceled)
34. (Canceled)

35. (Currently amended) A composition comprising the ~~double-stranded nucleic acid~~
siRNA molecule of claim 1 in a pharmaceutically acceptable carrier or diluent.